A former contractor at the ASX has alleged the securities exchange was “embarrassed” by governance failures relating to a $200 million technology modernisation program and sought to hide the issues from the Reserve Bank of Australia.
Telstra has reached an agreement with the consumer regulator after a court found the telco misled thousands of broadband customers about the speed of its budget internet provider, Belong.
Hall & Wilcox has struck back at proceedings by the liquidators for collapsed construction group Hastie, saying they have failed to specify why its $18.6 million legal bill incurred in suing two dozen builders is unreasonable.
Property valuer M3 Property has denied claims that its lease valuations were incorrect and led to tenants of Adelaide’s Rundle Mall being overcharged and says that if it is found liable, brokers CBRE and JLL should be on the hook as well.
An entity associated with the director of defunct Sydney builder Quasar Constructions has failed to hand over details about its assets to liquidators, prompting further orders with a warning from the court.
A judge has signed of on a settlement struck by the liquidator for failed financial services firm Babcock & Brown, which will resolve all remaining and future shareholder disputes, which have beleaguered the liquidator for 12 years.
Cryptocurrency exchanges will be required to hold an Australian Financial Services Licence under proposed legislation announced by assistant treasurer Dr Daniel Mulino.
Saying the appeals court committed “fundamental errors” in approaching their claim of loss, the applicants in failed cases against the Commonwealth Bank have appealed to the High Court, in a case that could clarity the elusive test for damages in shareholder class actions.
The Chief Justice of the Queensland Supreme Court has warned lawyers they could be referred to the legal watchdog or face a personal costs order if they file submissions that contain hallucinations produced by generative artificial intelligence.
Abbey Animal Health has managed only a “pyrrhic victory” in a patent case against rival Virbac over an antiparasitic drug, and must withdraw its Levamox Duo product from the market, a court has found.